Xeris Biopharma Holdings, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Xeris reported Q2 2026 net product revenue of $91.0M (+34% YoY), driven by Recorlev reaching $56.8M (+81% YoY). On June 11, 2026, the company exchanged $23.0M of its 8.00% Convertible Senior Notes due 2028 for $23.0M cash plus ~5.0M shares; remaining $10.5M holders converted to ~3.6M shares in July 2026, eliminating all 2028 Convertible Notes outstanding. A one-time non-cash $31M fair-value charge on the exchange drove Q2 net loss to $31.1M. FY2026 guidance tightened to $385–$390M total revenue.
Why this rating
Strong 34% product revenue growth and debt elimination are operationally positive; however, ~$33.5M debt reduction (4.6% of $731M market cap) is meaningful but not transformational. Net loss inflated by non-cash charge. Adjusted EBITDA +$6.7M signals improving unit economics.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.